Wenping Wang Positioning Drug Candidates in a Competitive Landscape - an integrated, data-driven approach
|
ME de Jonge(1), ADR Huitema(1), AC Tukker (2), SM van Dam(1), S Rodenhuis(2), JH Beijnen(1,2). Prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high-dose chemotherapy.
|
Dinesh de Alwis1, Sophie Callies1, James Wright2, Leon Aarons3 and Micheal Burgess1 Resisting population PK, the story of P-gp inhibition and co-administered chemotherapy.
|
Pedro Berraondo1, Gloria González-Aseguinolaza1, Iñaki F. Trocóniz2 Application of Pharmacokinetic/Pharmacodynamic Concepts to Modeling in Gene Therapy
|
A.S. Zandvliet(1), S. Yasuda(2), W. Copalu(3), J.H.M. Schellens(4,5), J.H. Beijnen(1,5), A.D.R. Huitema(1) A physiologically based population pharmacokinetic model describing the non-linear disposition and blood distribution of indisulam in Caucasian and Japanese patients
|
Mick Looby and Amy Racine An approach to formal decision making in exploratory development
|
Lena E Friberg(1), Geoffrey K Isbister(2), L Peter Hackett(3) and Stephen B Duffull(1) Pharmacokinetic-Pharmacodynamic Modelling of QT-Prolongation following Deliberate Self-Poisonings with Citalopram
|
Justin J Wilkins (1, 2), G Langdon (1), H McIlleron (1), Goonaseelan Pillai (3), Peter J Smith (1), Ulrika S H Simonsson (2) Challenges in modelling the pharmacokinetics of isoniazid in South African tuberculosis patients
|
S. Glatt(1), C Pitou (1), J. Yingling (1), L. Bueno (2), D. de Alwis (1), I.F Troconiz (2) Preclinical Population PK/PD of TGF beta RI Kinase inhibitor for Cancer
|
Alan Maloney(1), Klaas Zuideveld(2), Karin Jorga(2), Cornelia Weber(2), Nicolas Frey(2), Per Olsson(1), Eric Snoeck(1) An Application of Modelling and Simulation to Type 2 Diabetes: Development of a general drug-disease model based on a meta analysis of over 40 studies investigating 5 PPAR drugs
|
MC Kjellsson (1), PH Zingmark (1, 2), EN Jonsson (1), MO Karlsson (1) A Study Comparing the Performance of the Proportional Odds Model to that of the Differential Drug Effect Model for Cumulative Logits
|
Bergès A (1), Laporte S (1), Girard P (5), Epinat M (2), Zufferey P (3), Alamartine E (4), Decousus H (1,2), Mismetti P (1,2) for the PROPHRE-75 study Group*. Do we need a perfect basic structural model before exploring the covariate model? Example with enoxaparin
|
Xavière Panhard and France Mentré Non-linear mixed-effects models for tests of interaction or of lack of interaction in cross-over and parallel pharmacokinetic studies: application to the test of interaction between protease inhibitors and nucleoside analogs in HIV patients
|
P.M. Jauslin (1, 2), H.E. Silber (1), N. Frey (2), R. Gieschke (2), U.S.H. Simonsson (1), K. Jorga (2), M.O. Karlsson (1) A Disease Model Describing the Regulation of the Glucose-Insulin System in Diabetic Patients after IVGTT and OGTT
|
Andrew Hooker (1), A. J. Ten Tije (2), M. A. Carducci (3), H. Gelderblom (4), F. W. Dawkins (5), W. P. McGuire (6), J. Verweij (2), Mats O. Karlsson (1) and S. D. Baker (3). Population pharmacokinetic modeling of total and unbound docetaxel plasma concentrations in cancer patients with poor liver function
|
Donald R. Stanski, MD Model-Based Drug Development: A FDA Critical Path Opportunity
|
José Pinheiro(1), Chyi-Hung Hsu(1), and Fei Chen(2) Analyzing Event History Data with nlme in S
|
France Mentré History and new developments in estimation methods in nonlinear mixed-effects models
|
Pascal Girard and France Mentré A comparison of estimation methods in nonlinear mixed effects models using a blind analysis
|
Adrian Dunne Introduction to Categorical Data Analysis
|
Nick Holford PKPD Workshop 'An overview on how to use NONMEM for PKPD analyses'
|